Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Breast 2Genitourinary 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 7Breast Neoplasms 6Ovarian Neoplasms 5Stomach Neoplasms 4Colonic Neoplasms 4Rectal Neoplasms 3Lung Neoplasms 3Neoplasm Metastasis 2Melanoma 2Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Zollinger-Ellison Syndrome 1Vipoma 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Testicular Neoplasms 1Somatostatinoma 1Renal Insufficiency 1Prostatic Neoplasms 1Pheochromocytoma 1Non functioning pancreatic endocrine tumor 1Neuroendocrine Tumors 1Neoplasms, Unknown Primary 1Multiple Endocrine Neoplasia Type 2b 1Multiple Endocrine Neoplasia Type 2a 1Multiple Endocrine Neoplasia Type 1 1Locally Advanced Rectal Cancer 1Liver Neoplasms 1Liver Failure 1

Interventions

veliparib 1Telemedicine 1Salpingo-oophorectomy 1High-Throughput Nucleotide Sequencing 1Genetic Testing 1Genetic Counseling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary Breast and Ovarian Cancer Syndrome × veliparib × Gastrointestinal × Clear all
NCT00892736 2018-06-29

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

National Cancer Institute (NCI)

Phase 1 Completed
98 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Hereditary Breast and Ovarian Cancer Syndrome, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡